NZ540092A - Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors - Google Patents
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitorsInfo
- Publication number
- NZ540092A NZ540092A NZ540092A NZ54009203A NZ540092A NZ 540092 A NZ540092 A NZ 540092A NZ 540092 A NZ540092 A NZ 540092A NZ 54009203 A NZ54009203 A NZ 54009203A NZ 540092 A NZ540092 A NZ 540092A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- nr7r9
- heteroaryl
- aryl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42754402P | 2002-11-20 | 2002-11-20 | |
PCT/US2003/035670 WO2004046101A2 (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ540092A true NZ540092A (en) | 2007-06-29 |
Family
ID=32326558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ540092A NZ540092A (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
Country Status (6)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
CN1838959A (zh) * | 2003-08-18 | 2006-09-27 | 辉瑞产品公司 | Erbb2抗癌剂的给药方案 |
WO2005023315A2 (en) * | 2003-09-11 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy |
JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
US7851623B2 (en) * | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
AU2008320342B2 (en) | 2007-10-29 | 2012-07-26 | Natco Pharma Limited | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
CA2804190A1 (en) | 2009-07-02 | 2011-01-06 | Newgen Therapeutics, Inc. | Phosphorus containing quinazoline compounds and methods of use |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
JP6426194B2 (ja) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態及びその使用 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2017122205A1 (en) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2216796C (en) * | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0880508B1 (en) * | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ATE496035T1 (de) | 1998-03-31 | 2011-02-15 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
MXPA02012870A (es) | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
-
2003
- 2003-11-10 EP EP03768789A patent/EP1567506A4/en not_active Withdrawn
- 2003-11-10 CA CA002506503A patent/CA2506503A1/en not_active Abandoned
- 2003-11-10 NZ NZ540092A patent/NZ540092A/en not_active IP Right Cessation
- 2003-11-10 JP JP2004553551A patent/JP4611745B2/ja not_active Expired - Fee Related
- 2003-11-10 WO PCT/US2003/035670 patent/WO2004046101A2/en active Application Filing
- 2003-11-10 AU AU2003291394A patent/AU2003291394B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2003291394B2 (en) | 2009-06-25 |
JP4611745B2 (ja) | 2011-01-12 |
CA2506503A1 (en) | 2004-06-03 |
EP1567506A4 (en) | 2007-06-20 |
AU2003291394A1 (en) | 2004-06-15 |
WO2004046101A3 (en) | 2004-09-16 |
JP2006508979A (ja) | 2006-03-16 |
WO2004046101A2 (en) | 2004-06-03 |
EP1567506A2 (en) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088766B2 (en) | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | |
NZ540092A (en) | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | |
JP6673920B2 (ja) | Parg阻害化合物 | |
KR100816166B1 (ko) | 항증식제로서 유용한 신규한 벤조이미다졸린 유도체 | |
EP2090575B1 (en) | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | |
CA2290918C (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
JP4386967B2 (ja) | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 | |
KR101143246B1 (ko) | 벤즈이미다졸 유도체 | |
CA2845630C (en) | Amino quinazolines as kinase inhibitors | |
SK17102002A3 (sk) | Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu | |
KR20110023884A (ko) | 피리딘 화합물 | |
CA2673003A1 (en) | Quinazolines for pdk1 inhibition | |
JP2010513263A (ja) | ベンズイミダゾール誘導体 | |
CA2787083A1 (en) | Androgen receptor modulators and uses thereof | |
OA12734A (en) | Quinazoline derivatives for the treatment of abnormal cell growth. | |
AU2008298926A1 (en) | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists | |
AU2003281346B2 (en) | Quinazoline derivatives | |
JP2002322178A (ja) | 二環式環基置換された4−アミノ−ピリドピリミジン誘導体 | |
UA81915C2 (en) | Novel venzoimidazole derivatives useful as antiproliferative agents | |
JP2008540663A (ja) | キナーゼ阻害剤としての置換7,8−ジヒドロ−1h−ピリミド[4,5−b][1,4]ジアゼピン−4−アミン | |
KR20050073238A (ko) | 몰폴린기가 치환된 퀴나졸린 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 NOV 2016 BY COMPUTER PACKAGES INC Effective date: 20131126 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2017 BY COMPUTER PACKAGES INC Effective date: 20161018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2018 BY COMPUTER PACKAGES INC Effective date: 20171018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2019 BY COMPUTER PACKAGES INC Effective date: 20181018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2020 BY COMPUTER PACKAGES INC Effective date: 20191018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
LAPS | Patent lapsed |